At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 509 enrolled
Drug / intervention
Vancomycin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
In Brief
A Phase 2 clinical trial evaluating Vancomycin for Bacteremia. Completed, enrolled 509 participants across 15 sites in 2 countries.
Detailed Summary
The purpose of this study is to accurately determine the length of appropriate drug treatment for staphylococcal blood stream infection. The study seeks to address important information about the management of staphylococcal blood stream infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacteremia
CountriesSpain, United States
CollaboratorsNational Institutes of Health (NIH)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartFeb 2011
Primary CompletionMar 2017
TodayJul 2026
First PostedAug 31, 2010
Enrollment StartFeb 1, 2011
Primary CompletionMar 4, 2017
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 15.8 years ago
Interventions
Vancomycindrug
Duration
Vancomycindrug
Duration